

UNITED STATES

NUCLEAR REGULATORY COMMISSION

REGION IV

611 RYAN PLAZA DRIVE, SUITE 400 ARLINGTON, TEXAS 76011-8064

April 15, 1998

Idaho Cardiology Associates, P.A.
ATTN: Frederick R. Badke, M.D.
Radiation Safety Officer
300 East Jefferson Street, Suite 201
Boise. ID 83712

SUBJECT: NOTIFICATION OF AUTHORIZED USER (§35.14)

Dear Dr. Badke:

In accordance with 10 CFR 35.14, your letter dated April 7, 1998, is accepted as notification that you have permitted the individual (Dr. Raymond M. Thorpe) named in your letter referenced above to work as an authorized user pursuant to 10 CFR 35.13(b)(1). Note that Dr. Thorpe is authorized to use material identified in 10 CFR 35.200 limited to nuclear cardiology studies only. No further correspondence on this matter is required.

Please note that the notification process permits an individual to leave and return without further notification; however, notification is required when the authorized user's arrangement or commitment with the licensee is terminated (permanently discontinues performance of duties under the license).

If you have any questions regarding the above, please contact me at 817-860-8100.

Your cooperation is appreciated.

Sincerely,

Jacqueline D. Cook

Health Physicist

Nuclear Materials Licensing Branch

License: 11-27082-01 Docket: 030-32236 Control:466318

Enclosure:

10 CFR Part 35

1/1

Idaho Cardiology Assoc	ciates.	P.A.
------------------------	---------	------

-2-

DOCUMENT NAME: L:\AUNOTIFY\IDCARDAS.LTR

To receive a copy of this document, indicate in the box "C" - Copy without attachment/enclosure "E" - Copy with attachment/enclosure "N" - No Copy

RIV:NMLB		
JDCook GOCOXC		
04/15/98		

LICENSE FEE TRANSMITTAL License Fee Management Branch, ARM and Regional Licensing Sections BETWEEN LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / 1/1) COMMENTS Amount: Docket No: Control No: License No: Action Type: OTHER Renawa! License Correct Fee Paid Application may be processed for: Fee Category and Amount: REGION IV Amendment Check No.: APPLICATION ATTACHED
Applicant/Licensee:
Received Date: IDAHO CARDIOLOGY ASSOCIATES P. A. 980413 3034381 466742 111-27558-01 Notifications Signed Bulle Signed Program Code: 02201 Status Code: 0 Fee Category: 7C Exp. Date: 20020331 Fee Comments: Decom Fin Assur Reqd: N (FOR LFMS USE)
INFORMATION FROM LTS APR 2 2 1998



April 7, 1998

Frederick R. Badke, MD, FACC M. Eric Carter, MD, FACC Charles E. Eiriksson, MD, FACC Colin D. Lee, MD, FACC Melinda L. Marks, MD, FACC Mark G. Parent, MD, FACC Marshall F. Priest, MD, FACC Walter L. Seale, MD, FACC Steven L. Writer, MD, FACC

NRC Region IV Nuclear Materials Licensing Branch 611 Ryan Plaza Drive, Suite 400 Arlington, TX 78011-8084

Re: License 11-27558-01

Dear Sir or Madam:

In accordance with 10 CFR Part 35.14, this will serve as a notification that Raymond M. Thorpe, M.D., will be covering on an as-needed basis to interpret nuclear cardiology studies at this facility. Currently Dr. Thorpe is practicing at St. Luke's Regional Medical Center as an authorized user under St. Luke's license 11-27312-01 which you will find attached.

Thank you for your help in this matter. If there are any questions, please do not hesitate to contact me at (208)336-4141.

Sincerely,

Frederick R. Badke, M.D.

FRB/jmm

Enclosure

DT: 4/7/98

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10. Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore take by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

1年1年1日1年7年1年1年1日

Licensee			In accordance with letter dated May 20, 1996
St. Luke's Regional Medical Center 190 E. Bannock Boise, Idaho 83712			3. License number 11-27312-01 is amended in its entirety to read as follows:
			4. Expiration date May 31, 2004
			5. Docket or Reference No 030-32196/IDA-13-2
	roduct, source, and/or nal nuclear material	7. Cher form	nical and/or physical 8. Maximum amount that licensee may possess at any one time under this license
Α.	Any byproduct material identified in 10 CFR 35.100	Α.	Any radiopharmaceutical A. As needed identified in 10 CFR 35.100
В.	Any byproduct material identified in 10 CFR 35.200	В.	Any radiopharmaceutical B. As needed identified in 10 CFR 35.200, except generators
С.	Any byproduct material identified in 10 CFR 35.300	С.	Any radiopharmaceutical C. 2 curies identified in 10 CFR 35.300
D.	Any byproduct material identified in 10 CFR 35.400	D.	Any brachytherapy D. As needed source identified in 10 CFR 35.400
Ε.	Any byproduct material identified in 10 CFR 35.500		Sealed sources for E. As needed diagnostic devices identified in 10 CFR 35.500
F.	Uranium depleted in Uranium-235	F.	Cadmium plated metal F. As needed
G.	Cesium-137		Sealed source (ORIS/CBI G. 5100 curies Model CSL-15)

MATERIALS LICENSE SUPPLEMENTARY SHEET

11-27312-01

Docket or Reference Number 030-32196/IDA-13-2

Amendment No. 02

- Byproduct, source, and/or special nuclear material
- Chemical and/or physical form
- 8. Maximum amount that licensee may possess at any one time under this license

H. Cesium-137

- H. Sealed source
 (Registered pursuant to
 10 CFR 32.210 or
 equivalent Agreement
 State regulations)
- H. 120 millicuries

9. Authorized use

- A. Medical use described in 10 CFR 35.100.
- B. Medical use described in 10 CFR 35.200.
- C. Medical use described in 10 CFR 35.300.
- D. Medical use described in 10 CFR 35.400 and, for cesium-137, calibration of licensee's survey meters and personnel dosimeters.
- E. Medical use described in 10 CFR 35.500.
- F. Shielding in a linear accelerator.
- G. For use in CIS-US, Inc. Model IBL-437C irradiator for the irradiation of human blood and blood products.
- H. For use in a Victoreen Model 681 calibrator for calibration of the licensee's survey instruments.

CONDITIONS

10. Locations of use:

- A. 190 E. Bannock, Boise, Idaho.
- B. 151 E. Bannock, Boise, Idaho.
- 11. Radiation Safety Officer: Roger G. Stano, M.S.

Docket or Reference Number 030-32196/IDA-13-2

Amendment No. 02

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

A. HUMAN USE

Authorized Users	Material and Use
Ray M. Thorpe, M.D.	10 CFR 35.100, 35.200, and 35.500
Charles L. Robertson, M.D.	10 CFR 35.100, 35.200, and 35.500
Craig E. Leymaster, M.D.	10 CFR 35.100, 35.200, and 35.500
Peter A. Langhus, M.D.	10 CFR 35.100, 35.200, and 35.500
Todd B. Burt, M.D.	10 CFR 35.100, 35.200, and 35.500
Charles R. Carrasco, M.D.	10 CFR 35.100, 35.200, and 35.500
Richard Lane, M.D.	10 CFR 35.100, 35.200, and 35.500
Charles E. Smith, M.D.	10 CFR 35.300, 35.400, and depleted uranium
Richard C. Ripple, M.D.	10 CFR 35.300, 35.400, and depleted uranium
Ronald V. Dorn, M.D.	10 CFR 35.300, 35.400, and depleted uranium
James R. Maxwell, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500
Elaine N. Daniel, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500

NONHUMAN USE

- B. Licensed material identified in Item 7.H. shall be used by, or under the supervision of, Roger G. Stano, M.S.
- C. Licensed material identified in Item 7.G. shall be used by, or under the supervision and in the physical presence of, Roger Stano, or individuals who have been trained as specified in application dated April 18, 1994. The licensee shall maintain records of individuals designated as users.
- 13. A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

Docket or Reference Number 030-32196/IDA-13-2

Amendment No. 02

- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.
- C. In the absence of a certificate from a transferor indicating that a leak test has been made within 6 months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.
- D. Sealed sources need not be leak tested if:

1 職に 3 数は 3 数は 3 数は 3 数は 3 数は 3 デー

- (i) they contain only hydrogen-3; or
- (ii) they contain only a radioactive gas; or
- (iii) the half-life of the isotope is 30 days or less; or
- (iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or
- (v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- E. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(b)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region IV, 611 Ryan Plaza Drive, Suite 400, Arlington, Texas 76011, ATTN: Director, Division of Radiation Safety and Safeguards. The report shall specify the source involved, the test results, and corrective action taken.
- F. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to Perform such services.

MATERIALS LICENSE SUPPLEMENTARY SHEET

11-27312-01

Docket or Reference Number 030-32196/IDA-13-2

Amendment No. 02

The licensee shall not perform repairs or alterations of the irradiator involving removal of shielding or access to the licensed material. Removal, replacement, and disposal of sealed sources in the irradiator shall be performed by a person specifically licensed by the Commission or an Agreement State to perform such services.

- The procedures contained in CIS-US, Inc. instruction manual for the Model IBL-437C device shall be followed and a copy of this manual shall be made available to each person using or having responsibility for the use of the device.
- Sealed sources containing licensed material shall not be opened or sources removed 16. from source holders by the licensee.
- The licensee shall conduct a physical inventory every 3 months to account for all sources and/or devices received and possessed pursuant to 10 CFR 35.59, 10 CFR 35.400 and 10 CFR 35.500 and every 6 months for all other sources and/or devices.
- In addition to the possession limits in Item 8, the licensee shall further restrict 18. the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated March 17, 1994
 - Letter dated April 18, 1994 B.
 - Letter dated April 27, 1994
 - D. November 4, 1994
 - Letter dated December 12, 1994
 - F. Letter dated May 20, 1996
 - Additional information received by facsimile on July 16, 1996

Ву

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

APR 1 3 1908

JUL 17 1996

Common Signed By D. Burks

Date

Nuclear Materials Licensing Branch Region IV Arlington, Texas 76011